The story of Sildenafil presents a interesting case for observers in the medicinal sector. While initially a phenomenal success, producing billions, the patent end and the subsequent flood of cheaper competitors have significantly affected income. This poses questions about the ongoing sustainability of similar medication projects and suggests t… Read More